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Abstract
Background: There were an estimated 7 million people living with diabetes in Pakistan in 2014, and
this is predicted to reach 11.4 million by 2030.
Aim: To assess if an integrated care package can achieve better control of diabetes.
Design & setting: The pragmatic cluster randomised controlled trial (cRCT) was conducted from
December 2014–June 2016 at 14 primary healthcare facilities in Sargodha district. Opportunistic
screening, diagnostic testing, and patient recording processes were introduced in both the control
’testing, treating, and recording’ (TTR) arm, and the intervention ’additional case management’
(ACM) arm, which also included a clinical care guide and pictorial flipbook for lifestyle education,
associated clinician training, and mobile phone follow-up.
Method: Clinics were randomised on a 1:1 basis (sealed envelope lottery method) and 250 patients
recruited in the ACM arm and 245 in the TTR-only arm (age 25 years and HbA1c >7%). The
primary outcome was mean change in HbA1c (%) from baseline to 9-month follow-up. Patients and
staff were not blinded.
Results: The primary outcome was available for n = 238/250 (95.2%) participants in the ACM arm
and n = 219/245 (89.4%) participants in the TTR-only arm (all clusters). Cluster level mean outcome
was -2.26 pp (95% confidence intervals [CI] = -2.99 to -1.53) for the ACM arm, and -1.44 pp (95% CI
= -2.34 to -0.54) for the TTR-only arm. Cluster level mean ACM–TTR difference (covariate-
unadjusted) was -0.82 pp (95% CI = -1.86 to 0.21; P = 0.11).
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Conclusion: The ACM intervention in public healthcare facilities did not show a statistically
significant effect on HbA1c reduction compared to the control (TTR-only) arm. Future evaluation
should assess changes after a longer follow-up period, and minimal care enhancement in the
comparator (control) arm.
How this fits in
Integrated care at primary and secondary level public health facilities is an approach currently being
recommended for extended coverage and continuity of diabetes care. Diabetes care includes both
clinical and lifestyle modification components. In Pakistan, as most other developing countries, con-
textualised integrated care has never been evaluated so evidence was required to inform further
measures for scaling the integrated diabetes care in low income country setting. To widen the scope
of learning, a process evaluation of integrated care delivery was also conducted and published.1
Introduction
There were an estimated 7 million people living with diabetes in Pakistan in 2014,2 with the number
increasing by about 250 000 each year and predicted to reach 11.4 million by 2030.3 Diabetes con-
tributes to 3% of the total deaths in Pakistan.4 At least 3.3 million (48%) patients with diabetes in
Pakistan were undiagnosed in 2014,5 mostly due to obesity-related gradual adult-onset type 2 dia-
betes mellitus. Type 1 diabetes is a less common, severe, and rapid onset disease, requiring insulin
injections and specialist care. In this study and article, ‘diabetes’ refers specifically to type 2 diabetes
mellitus. Diabetes, hypertension, and the related cardiovascular diseases comprise the highest bur-
den of non-communicable diseases (NCDs).
In Pakistan, a National Action Plan for Non-Communicable Disease Prevention and Control (NAP–
NCD) was released in May 2004.6 This plan emphasises prevention, screening, management, moni-
toring, and surveillance of NCDs.7 However, there has been little in the way of implementation,
mainly due to the lack of an intervention package for integrating diabetes prevention and control at
the primary healthcare facility level. In Pakistan, rural health centres and sub-district hospitals are the
primary healthcare facilities responsible for providing diagnosis, treatment, and prevention for both
communicable diseases and NCDs. However, doctors and 3-year trained allied professionals (known
as ‘paramedics’ in Pakistan) involved in diabetes care at this level lack standardised guidelines and/
or operating practices to diagnose, treat, educate, follow-up, and report on patients with diabetes,
and there are inadequate resources, such as diagnostic consumables and drugs, to support uninter-
rupted diabetes care; no records are kept except of the prescription, for example. Historically, dia-
betes and associated hyperlipidaemia would be managed by hospital specialists, but much of the
population lacked access. Specialists in internal medicine, endocrinology, cardiology, ophthalmol-
ogy, and renal medicine who care for patients with diabetes complications are only available at the
‘district’ level hospitals (a district in Pakistan typically has a population of 1–3 million); the sub-district
level hospitals and rural health centres have general doctors who usually see patients who self-pres-
ent for care. Referral may occur for seriously ill people as an emergency. Referral for specialist
assessment and opinion is less common, and referral back for continuing care is even rarer; that is,
links between primary healthcare centres and district hospitals are usually lacking, and the district
health system is does not currently provide quality care for patients with diabetes and associated
hyperlipidaemia, or complications such as strokes.
A systematic review of 11 studies with 2616 persons with diabetes reported that structured, cul-
turally competent interventions improved patient-related outcomes such as glycaemic control, lipid
profiles, and blood pressure.8 A systematic review in rural areas9 had similar findings. Another
review, also from the developed country setting, found that chronic disease management together
with patient interventions were effective, while those solely targeting providers were beneficial only
if baseline control was poor. There are few studies or systematic reviews of diabetes care models in
lower and/or middle income countries (LMICs). One review identified gaps as compared to interna-
tional standards, and that most interventions focused only on the provider and not the patient.10
Another identified that comprehensive care models — which included collaboration, education,
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standardisation, resource optimisation (as in the present intervention), and technological innovation
— were most successful.11
Based on the WHO ‘Package of Essential Non-communicable Disease Interventions for Primary
Health Care’ (‘PEN’) guidance,12 an intervention package was developed for the delivery of quality
primary health care through the district healthcare system. This package included two main compo-
nents: 1) testing, treating, and recording (TTR), including the screening of overweight adults and
maintenance of patient records; and 2) an additional case management (ACM) package, including
standardised education on healthy lifestyle (that is, diet, exercise, and smoking cessation), standar-
dised drug treatments for diabetes and associated hyperlipidaemia, and active clinical follow-up of
patients. The package was then piloted in four primary healthcare facilities, where the feasibility of
care protocols was assessed through analysis of patient records, as well as observations and inter-
views. Based on the findings, the details of the screening, recording and care package were refined.
In Pakistan, at the primary healthcare level, there was a lack of standard screening, testing, and
recording practices, as well as case management and lifestyle education guides for NCDs. Using a
cRCT, an NCD screening, testing, and recording package was implemented across all trial facilities
to allow uniform recruitment and assessment of patients with diabetes. In intervention facilities, an
additional case management package was then implemented, aimed at improving’ the glycaemic
control and lipid profiles of patients with type 2 diabetes, and its effectiveness was evaluated.
Method
Study design, setting, and participants
A parallel arm, cRCT was conducted between December 2014–June 2016 in the Sargodha district in
Punjab, Pakistan. In addition to a district-level secondary hospital, 14 rural health centres and 6 sub-
district hospitals provide public funded care to 3.1 million population in the district (2:1 rural–urban
split). After checking the in-place basic services (such as laboratory) at each eligible site with the dis-
trict health office, nine rural health centres, and five sub-district hospitals (total n = 14) were
recruited and randomised into the trial. In each of the 14 selected clusters, communal consent for
the catchment population’s participation in the trial was taken from the community leaders who
were identified and invited with the help of staff at respective health facility. These community lead-
ers represented a) religious leaders, b) political leaders (local woman councillor), c) health represen-
tative of union council, d) school teachers, e) local press reporters, and f) local businessmen. The
study involves only the outpatient department of facilities, which have general practice doctors see-
ing un-referred primary care patients. A cluster design was used because it would not have been fea-
sible to expect providers to effectively apply or withhold many of the intervention components
based on a patient’s treatment allocation (for example, standardised diagnosis), and because of the
risk of contamination between patients.
Patients were eligible if they were understood by the facility doctor to be newly diagnosed with
diabetes (fasting blood glucose 126; random blood glucose 200), aged 25 years, not pregnant,
and not likely to move away from their initial catchment area during follow-up. The authors
attempted to recruit all eligible patients attending the selected public facilities between December
2014–September 2015. Informed consent was obtained from patients using a standard consent form
administered by an allied professional (paramedic) at the respective public healthcare facility.
Randomisation and blinding
The 14 facilities were randomised to the TTR-only or the ACM arm on a 1:1 basis using a lottery
method with sealed envelopes. In the presence of a five member committee, a staff member from
the provincial directorate randomly selected seven envelopes for each arm from among 14 sealed
envelopes, each containing a recruited facility name. The committee consisted of the Director Non-
Communicable diseases in Punjab, two representatives from the Directorate General of Health Serv-
ices Punjab, and two Association for Social Development representatives. It was not possible to blind
healthcare providers or patients to the treatment allocation due to the nature of the trial procedures,
such as provider training and patient education. However, the laboratory staff who carried out the
testing for outcomes were blinded to the cluster allocation.
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Procedures
In the TTR-only arm facilities, the existing situation meant that there was training on screening, diag-
nosis, testing, and recording, but no operational guidelines available for doctors or allied professio-
nals on the additional case management of diabetes and related high cholesterol. Clinicians
therefore managed such conditions according to their existing knowledge and practices, and with-
out reference to any specific guidelines and/or tools. The district health office was requested to
make the same drugs available at all facilities, through the routine district drug system, though with
some top up in the ACM facilities. For this study, the interventions/ resources provided in both arms
were over and above usual care, and included: a) equipment and supplies for patient screening at
the first visit, including weight and height scales, glucometers and glucose strips, and electronic
sphygmomanometers; b) staff training on patient screening and diagnosis at the first visit; and c) a
patient card for recording core biomedical measures at baseline and follow-ups. Patients were also
given vouchers so that they could get glycated haemoglobin (HbA1c) and serum cholesterol mea-
sured at no cost at specified laboratories. All these TTR inputs were the same for both arms.
In the ACM arm, in addition to the TTR inputs above, all facilities received additional case man-
agement ACM enhancements including: a) a context-adapted desk guide for step-by-step manage-
ment of diabetes and associated high cholesterol, and information about referral of severe or
complex cases; b) patient education on diabetes care and lifestyle change, using contextualised
communication materials; and c) monthly appointment review and reminders (through SMS text mes-
saging). A more detailed description of the TTR and ACM procedures is provided in Figure 1 .
Two key diabetes drugs, metformin and sulphonylurea, were available both in the TTR-only and
ACM arm facilities, mainly through the respective district health office. However, the ACM arm desk-
guide included a step-by-step approach to adding drugs and amending dosage of diabetes drugs,
as well as recommending a statin if patient had raised cholesterol. Further details are included in the
process evaluation study published alongside the results of this trial,1 and the guides and tools are
available elsewhere.13
Data collection and outcomes
The inclusion of patients happened at an expected pace (as informed by piloting experience),
although this pace varied slightly across facilities. All data were recorded on patients’ chronic dis-
ease cards. At both sub-district hospitals and rural health centres, the facility doctor recorded the
clinical data (for example, diagnosis, prescription, and blood pressure) and the allied professional
recorded the nonclinical data (such as age and weight) at diagnosis and at eight subsequent monthly
follow-up visits. The doctor, using electronic sphygmomanometer during clinical consultation,
checked and recorded the blood pressure. A designated allied staff member at the facility checked
and recorded the fasting and/or random blood glucose levels using a glucometer and strips. A des-
ignated non-public laboratory collected samples and tested for HbA1cand serum cholesterol levels,
and an allied staff member at the facility noted the results on the patient’s card. Data were then
transferred from patient record cards and entered into an SPSS database. The research team tried
to contact patients who did not return for their 9-month follow-up appointment for 3 months before
they were classed as lost to follow-up.
All outcomes were recorded at the patient level. The primary outcome was the percentage point
change in HbA1c, the internationally recognised standard test (of glucose control over the previous
3 months), between baseline and 9 months. Secondary outcomes were the change between baseline
and 9 month in systolic blood pressure (mmHg), diastolic blood pressure (mmHg), and total serum
cholesterol (mg/dL), and 9-month glycaemic control (HbA1c <7%) and hypertension control (systolic
blood pressure <140 mmHg).
Statistical analysis
Data were single entered into SPSS (version 17). To minimise data errors, data quality assurance pro-
cedures were used, including training of data entry operators and checking data entry quality at reg-
ular intervals.14
All data were analysed according to the original allocation of clusters, but patients with missing
outcome and/or covariate data were excluded as necessary (that is, depending on whether the data
were required for the analysis). Cluster-level methods of analysis were used that were suitable for
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cRCTs with relatively few clusters per arm,15 producing crude and covariate-adjusted results. All
adjusted analyses controlled for patient sex, age, number of schooling years, baseline BMI, and
smoking status, as well as relevant baseline outcomes. All analyses exclude patients’ missing out-
come and/or covariate data, as required by the relevant analysis. In addition, change in HbA1c and
glycaemic control analyses were also adjusted for baseline hypertension status, cholesterol level,
and HbA1c level. Change in systolic blood pressure and hypertension control analyses were also
adjusted for baseline cholesterol level and systolic blood pressure. Change in diastolic blood pres-
sure analysis was also adjusted for baseline cholesterol level and diastolic blood pressure. Change in
cholesterol analysis was also adjusted for baseline cholesterol and hypertension status
Statistical significance was set at the 5% level, and two-sided P values were calculated. More
details on statistical analyses are available from the author on request.
Figure 1. Diabetes intervention (ACM) and control (TTR-only) care package details. ACM = additional case management. BP = blood pressure. FBG =
fasting blood glucose. RBG = random blood glucose. TTR = testing, treating, and recording.
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Sample size calculation
For the primary outcome, the authors aimed to be able to detect a 0.5 percentage point decrease
in HbA1c from baseline to 9 months in the ACM arm compared to the TTR-only arm. A standard
deviation of 2% was assumed,16 as well as an intracluster correlation coefficient of 0.018,17 and a
10% loss to follow-up rate. A significance level of 5% was set. To detect the minimum clinically
important difference of 0.5 percentage points between the mean change (baseline to follow-up) in
HbA1c for the ACM arm compared to the TTR-only arm with 80% power required a total sample
size of 448 patients across 14 facilities. The research team therefore aimed to recruit an average of
32 patients per cluster over 6 months.
Results
Patients were recruited in the trial during the period August 2014–September 2015; and the follow-
up and outcome measurements were completed by the end of July 2016. Figure 2 shows the trial
design flowchart. Baseline characteristics of trial patients are shown in Table 1. There were no sub-
stantial differences in patient characteristics between the arms.
Figure 2. CONSORT trial flow chart
ACM = additional case management. TTR = testing, treating, and recording.
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There was no statistically significant difference in the baseline to 9-month follow-up change in
HbA1c between the ACM and the TTR-only arms, although there was a clear reduction in HbA1c
between baseline and follow-up within both arms (see Table 2). There were also no statistically sig-
nificant treatment effects for any of the secondary outcomes, as shown in Table 2. These results
were consistent between the crude and covariate-adjusted analyses. For all crude analyses, except
for the adherence and cholesterol outcomes, data were available for 238/250 (95.2%) participants in
the ACM arm and for 219/245 (89.4%) participants in the TTR arm. For the adherence outcome,
data were available for 250/250 (100%) participants in the ACM arm and 245/245 (100%) participants
in the TTR arm, and for the cholesterol outcome data were available for 234/250 (93.6%) participants
in the ACM arm and 219/245 (89.4%) participants in the TTR arm. For all adjusted analyses, except
for the adherence and cholesterol outcomes, data were available for 232/250 (92.8%) participants in
the ACM arm and 218/245 (89%) participants in the TTR arm. For the adjusted analysis of the adher-
ence outcome, data were available for 243/250 (97.2%) participants in the ACM arm 228/245
(93.1%) participants in the TTR arm, and for the cholesterol outcome data were available for 228/
250 (91.2%) participants in the ACM arm and 218/245 (89%) participants in the TTR arm. The intra-
cluster correlation coefficient for the primary outcome was 0.046 (95% CI = 0.01 to 0.149) across
both arms, 0.026 (95% CI = -0.007 to 0.199) for the ACM arm and 0.044 (95% CI = -0.001 to 0.26)
for the TTR alone arm. There was also no evidence for any effect modification of a possible treat-
ment effect on the primary outcome by sex (further information available from the author on
request).
Table 1. Baseline characteristics of clusters and patients
Characteristics ACM, n (%) TTR-only, n (%)
Clusters
Total 7 (100.0) 7 (100.0)
Doctors
Male 7 (100.0) 7 (100.0)
Female 0 (0.0) 0 (0.0)
Paramedics
Male 5 (71.4) 3 (42.9)
Female 2 (28.6) 4 (57.1)
Participants in clusters
Total 250 (50.5) 245 (49.5)
Mean cluster size (SD) 35.7 (± 10.4) 35 (± 15.4)
Sex
Male 92 (36.8) 97 (39.6)
Female 158 (63.2) 148 (60.4)
Mean age, years (SD) 46.1 (± 10.4) 46.1 (± 9.7)
Mean education ,years (SD) 3.5 (± 4.4) 4.9 (± 4.8)
Mean BMI, kg/m2 (SD) 31.9 (± 7.8) 32.8 (± 8.1)
Hypertensive 60 (24.0) 68 (27.8)
Mean fasting blood sugar, mg/dL (SD) 216.3 (± 56.5) 203.8 (± 52.7)
Mean random blood sugar, mg/dL (SD) 303.3 (± 81.6) 292.7 (± 69.5)
Mean HbA1c% (SD) 10.4 (± 2.4) 10.0 (± 2.4)
Mean systolic blood pressure, mmHg (SD) 129.9 (± 16.6) 130.1 (± 17.6)
Mean diastolic blood pressure, mmHg (SD) 84.7 (± 9.4) 87.0 (± 13.3)
Mean total serum cholesterol, mg/dL (SD) 192.6 (± 51.8) 193.0 (± 46.6)
’Hypertensive’ defined as baseline systolic blood pressure >140 mmHg.
ACM = additional case management. BMI = body mass index. TTR = testing, treating, and recording
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The adherence to monthly follow-up — that is, 4 visits out of the 8 monthly follow-up visits rec-
ommended — was 75.6% for the ACM arm (which included measures such as SMS messaging to
improve attendance) and 30.2% for the TTR only arm. The mean difference in adherence between
two arms was 45.4% (95% CI = 38% to 53%; P = 0.001).
Discussion
Summary
There was no statistically significant difference between the ACM and TTR-only arms for the primary
outcome of change in HbA1c. This lack of difference in blood glucose control might have occurred
because of the following two limitations: first, the TTR-only (control) arm was more effective than
existing routine care. However, to have comparable clients enrolled and outcomes recorded, train-
ing and equipment was provided and drug supply also facilitated in the TTR-only arm. This is very
likely to have led to a better level of care in the TTR-only facilities than would normally be encoun-
tered in usual care practice. As a result, outcome measures in the TTR-only arm facilities, such as
HbA1c and serum cholesterol, might have been better than those usually seen in routine care. In
TTR-only patients, the HbA1c decrease at 9 months was -1.44 pp (95% CI = -2.34 to -0.54), and -
2.26 pp (95% CI = -2.99 to -1.53) for the ACM arm patients. These are likely to be clinically signifi-
cant reductions as the risk of diabetes complications drops by 35% for every percentage point
decrease in HbA1c.18 In short, an unanticipated positive effect of the TTR on the primary outcome
may have been a key reason for the trial not showing a statistically significant difference between
the arms. Clearly, initial assumptions around the expected effect size from the intervention were not
correct, which may be primarily due to the unanticipatedly large, positive effect of the TTR interven-
tion. Therefore, assuming a smaller effect size and using a larger sample size may have resulted in
the detection of a statistically significant intervention effect.
Second, the 9-month follow-up duration might have not been enough for the ACM intervention
to achieve the desired reduction in blood glucose of diabetic patients. The ACM intervention starts
with a minimum level of treatment and then gradually becomes more rigorous, adding drugs and
increasing dosage during monthly follow-up visits, as needed. This gradual enhancement might have
contributed to relatively slow progress in glucose control in the ACM intervention, leading to a lack
of significant difference between TTR-only and ACM facilities at 9-month follow-up in the trial.
Table 2. Primary and secondary outcome results
ACM arm
(clusters, n = 7)
TTR-only arm
(clusters, n = 7)
Crude ACM-TTR difference
(95% CI); P valuea
Adjusted ACM-TTR
difference (95% CI); P valuea
Mean outcome (95% CI)b
Primary outcome
Change in HbA1c (pp)c -2.26pp (-2.99 to -1.53) -1.44pp (-2.34 to -0.54) -0.82pp (-1.86 to 0.21); 0.11 -0.57pp (-1.44 to 0.29); 0.17
Secondary outcomes
Adherenced 75.64% (45.56 to 105.71%) 36.29% (3.9 to 68.67%) 39.35pp (-0.02 to 78.73); 0.0501 36.06pp (-0.78 to 72.9); 0.054
Glycaemic controle 45.04% (32.48 to 57.6%) 34.86% (16.15 to 53.57%) 10.18pp (-10.21 to 30.57); 0.29 10.87pp (-7.92 to 29.67); 0.23
Change in SBP (mmHg)c 2.33 (-0.1 to 4.76) 1.47 (-4.32 to 7.26) 0.86 (-5.05 to 6.77); 0.75 1.3 (-3.41 to 6.01); 0.56
Change in DBP (mm Hg)c 2.81 (-1.04 to 6.66) 0.68 (-4.34 to 5.69) 2.13 (-3.54 to 7.81); 0.43 0.29 (-1.93 to 2.51); 0.78
Hypertension controlf 73.2% (61.92 to 84.49%) 72.47% (59.36 to 85.58%) 0.73pp (-14.71 to 16.17); 0.92 0.0pp (-12 to 12.95); 0.93
Change in total serum
cholesterol (mg/dL)c
-5.24 (-19.82 to 9.34) 2.75 (-5.73 to 11.22) -7.99 (-23.43 to 7.45); 0.27 -5.79 (-20.22 to 8.65); 0.4
ACM = additional case management. CI = confidence intervals. TTR = test, treat, and record. PP = percentage points.
aAll ACM–TTR differences (that is, ACM effect size measures) are based on analysis of cluster-level (mean/proportion) outcomes. bMean outcomes and their 95% confi-
dence intervals are based on cluster-level (mean/proportion) raw outcome data. cAll change outcomes are calculated as outcome at 9 months minus outcome at baseline.
dAdherence defined as attendance of 4 follow-up appointments within 9 months. eGlycaemic control defined as 9-month HbA1c (%) <7%. fHypertension control defined
as 9-month systolic blood pressure 140 mmHg.
All analyses exclude patients’ missing outcome and/or covariate data as required by the relevant analysis.
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Strengths and limitations
The main strength of this trial is that it was conducted within the routine health care using the same
staff and essential drugs. It was designed and developed to be potentially replicable and sustainable
in the routine system, and the intervention and research protocols and tools were piloted before the
trial. However, healthcare providers and patients were not blinded to the treatment arm allocation;
in addition, the trial was not meant to assess changes in diet or exercise.
Comparison with existing literature
A randomised controlled trial evaluating the addition of a structured education manual for general
practice nurses in a high income context (the UK) found no differences in HbA1c between enhanced
care (ACM) and current practice (TTR-only) arms.19 However, this trial’s ACM package was more
than just the provision of education materials for healthcare providers, and health services context
was also different since Pakistan is a low income setting. In the United Arab Emirates, a standard
package of care that included education of healthcare professionals and patients, support for diabe-
tes care, and improved recording of clinical information20 showed improvements in some but not all
processes of quality care, as in the present trial. A systematic review has also found that a package
of complex interventions, rather than a single intervention, resulted in better processes of care and
enhanced21 patient outcomes,22 and a systematic review in rural areas9 had similar findings. Another
review, from a developed country setting, found that chronic disease management together with
patient interventions were effective, while those solely targeting providers were beneficial only if
baseline control was poor, as was the case in the present trial. A review of diabetes care models in
LMICs identified gaps in guidelines compared to international standards, and that most focused on
the provider and not the patient; the present intervention focused on both.10 Another identified
that comprehensive care — incorporating collaboration, education, standardisation, resource optimi-
sation (as in the present intervention), and technological innovation — was a common feature of suc-
cessful models.11
The present trial showed better patient adherence to the monthly follow-up visits to be examined
and collect free of cost drugs. The enhanced patient education, SMS messaging, and telephone
reminder components of the ACM intervention are likely to have contributed to improved adherence
to the monthly follow-up. Mobile phones have also been used to ensure regular follow-up of patients
in rural areas of Pakistan, and this has been shown to be helpful in lowering and normalising HbA1c
levels.23 The reminder letters also improved patient attendance and retention for diabetes and
hypertension management in rural health districts in Cameroon.24
Implications for research
Future evaluation of ‘step by step’ integrated care may better be assessed after a period of follow-
up exceeding 9 months. Also, a further study to separately evaluate the effectiveness of the two
components of an intervention (that is, clinical care and lifestyle modification) would further add to
current knowledge.
This pragmatic randomised controlled trial at public healthcare facilities in Pakistan did not show
a statistically significant difference in HbA1c between intervention and control arms (although clini-
cally relevant reductions were found within both arms between baseline and endline). The strength-
ening of care in the control arm (above routine care) and relatively short duration of follow-up (of 9
months) prior to the outcome measurement cannot be ruled out as plausible explanations for the
lack of treatment effect. However, patient adherence to monthly follow-up visits was found to have
improved in the intervention arm compared to the control arm.
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